IR Biosciences Holdings, Inc.
IRBS
$0.00
$0.000.00%
OTC PK
| 12/31/2010 | 09/30/2010 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 17.60% | -72.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.60% | -72.17% | |||
| Operating Income | -17.60% | 72.17% | |||
| Income Before Tax | 87.71% | -336.52% | |||
| Income Tax Expenses | 100.00% | -- | |||
| Earnings from Continuing Operations | 87.70% | -336.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 87.70% | -336.16% | |||
| EBIT | -17.60% | 72.17% | |||
| EBITDA | -17.77% | 72.29% | |||
| EPS Basic | 92.62% | -333.55% | |||
| Normalized Basic EPS | -48.85% | 69.26% | |||
| EPS Diluted | 92.62% | -333.55% | |||
| Normalized Diluted EPS | -48.85% | 69.26% | |||
| Average Basic Shares Outstanding | 1.58% | 9.95% | |||
| Average Diluted Shares Outstanding | 1.58% | 9.95% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||